z-logo
open-access-imgOpen Access
The Involvement ofNRF2in Lung Cancer
Author(s) -
Alison K. Bauer,
Thomas Hill,
CarlaMaria Alexander
Publication year - 2013
Publication title -
oxidative medicine and cellular longevity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.494
H-Index - 93
eISSN - 1942-0900
pISSN - 1942-0994
DOI - 10.1155/2013/746432
Subject(s) - lung cancer , cancer research , computational biology , medicine , biology , chemistry , oncology
Nuclear factor, erythroid-derived 2, like 2 ( NRF2 ) is a key regulator of antioxidants and cellular stress responses. The role of NRF2 in pulmonary neoplasia, a diverse disease for which few biomarkers exist, is complicated and appears to depend on several main factors including the existence of activating mutations in NRF2 and/or loss of function mutations in KEAP1 and the stage of carcinogenesis studied, particularly in the mouse models tested. Therapeutic strategies for lung cancer targeting NRF2 have observed mixed results, both anti- and protumorigenic effects; however, these differences seem to reflect the mutation status of NRF2 or KEAP1 . In this paper, we will discuss the studies on human NRF2 and the mechanisms proposed, several mouse models using various mice deficient in NRF2 , as well as xenograft models, and the chemotherapeutic strategies using the NRF2 pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom